Health Trials

ER+/HER2- Breast Cancer

3

Review clinical trials related to ER+/HER2- Breast Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) combined with toripalimab and chemotherapy as neoadjuvant therapy for ER+/HER2- breast cancer.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityUpdated: Jul 14, 2026Locations: 1
Eligibility criteria

Female patients aged 18-75 years. [+3]

Female patients during pregnancy or lactation. [+6]

Read more
Status: Recruiting

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

A Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer. This clinical trial aims to explore the role of FWD1802 in the ER+/HER2- advanced breast cancer patient population. The primary objectives are to address the following questions: Phase I Study: Determine the Recommended Phase II Dose (RP2D) and/or Maximum Tolerated Dose (MTD) of FWD1802 in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. Phase II Study: To evaluate the efficacy of FWD1802 at the RP2D in patients with ESR1-mutated ER-positive/HER2-negative locally advanced or metastatic breast cancer, using objective response rate (ORR) as the efficacy endpoint.

Participants needed: 99
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Forward Pharmaceuticals Co., Ltd.Updated: Feb 10, 2026Locations: 22
Eligibility criteria

Voluntarily participate in the clinical trial and sign the informed consent form... [+20]

Leptomeningeal metastases, carcinomatous meningitis, spinal cord compression, or... [+37]

Read more
Status: Not yet recruiting

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.

Participants needed: 55
Trial details
Phase: Phase 2Age: 18-70Biological sex: FemaleType: InterventionalSponsor: West China HospitalUpdated: Aug 7, 2025
Eligibility criteria

Females aged 18-70 years; [+11]

Inflammatory BC； [+15]

Read more